AASLD GUIDELINES Bundle (free trial)

Hemochromatosis

AASLD GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: http://eguideline.guidelinecentral.com/i/100169

Contents of this Issue

Navigation

Page 9 of 9

Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) Strength of Recommendation Criteria Strong (1) Factors influencing the strength of the recommendation included the quality of the evidence, presumed patient-important outcomes, and cost Weak (2) Variability in preferences and values, or more uncertainty. Recommendation is made with less certainty, or higher cost or resource consumption Quality of Evidence Criteria High (A) Further research is unlikely to change confidence in the estimate of the clinical effect Moderate (B) Further research may change confidence in the estimate of the clinical effect Low (C) Further research is very likely to impact confidence on the estimate of clinical effect Abbreviations AASLD, American Association for the Study of Liver Diseases; ALT, alanine aminotransferase; AST, aspartate aminotransferase; C282Y, Cys282Tyr mutation; H63D, His63Asp mutation; HAMP, hepcidin; HCC, hepatocellular carcinoma; HH, hereditary hemochromatosis; HIC, hepatic iron concentration; HJV, hemojuvelin; Tf R2, transferrin receptor-2; TS, transferrin saturation Source Bacon BR, Adams PC, Kowdley KV, Powell LW, Tavill AS; American Association for the Study of Liver Diseases. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011 Jul;54(1):328-43. PMID: 21452290 Disclaimer This Guideline attempts to define principles of practice that should produce high-quality patient care. It focuses on the needs of primary care practice, but also is applicable to providers at all levels. This Guideline should not be considered exclusive of other methods of care reasonably directed at obtaining the same results. The ultimate judgment concerning the propriety of any course of conduct must be made by the clinician after consideration of each individual patient situation. Neither IGC, the medical associations, nor the authors endorse any product or service associated with the distributor of this clinical reference tool. HEM121201b 5740 Executive Drive��� Suite 218 Baltimore, MD 21228��� TEL: 410-869-3332��� ������ FAX: 410-744-2150��� For additional copies: orders@GuidelineCentral.com Copyright �� 2013 All rights reserved

Articles in this issue

Links on this page

Archives of this issue

view archives of AASLD GUIDELINES Bundle (free trial) - Hemochromatosis